Sanofi

OTCPK:SNYN.F Stock Report

Market Cap: US$135.0b

Sanofi Valuation

Is SNYN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNYN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$256.63
Fair Value
57.8% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: SNYN.F ($108.37) is trading below our estimate of fair value ($256.63)

Significantly Below Fair Value: SNYN.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNYN.F?

Key metric: As SNYN.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SNYN.F. This is calculated by dividing SNYN.F's market cap by their current earnings.
What is SNYN.F's PE Ratio?
PE Ratio22.9x
Earnings€5.68b
Market Cap€130.27b

Price to Earnings Ratio vs Peers

How does SNYN.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SNYN.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.4x
ZTS Zoetis
31.7x10.0%US$77.1b
PFE Pfizer
35.2x8.1%US$152.5b
MRK Merck
20.6x12.1%US$250.3b
JNJ Johnson & Johnson
26x8.4%US$366.3b
SNYN.F Sanofi
22.9x13.3%US$130.3b

Price-To-Earnings vs Peers: SNYN.F is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (28.4x).

Price to Earnings Ratio vs Industry

How does SNYN.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.6xn/aUS$2.01b
KPRX Kiora Pharmaceuticals
2.2x0.2%US$12.09m
CNNC Cannonau
0.3xn/aUS$96.73k
SEEL.Q Seelos Therapeutics
0.0003xn/aUS$1.31k
SNYN.F 22.9xIndustry Avg. 18.4xNo. of Companies6PE01224364860+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SNYN.F is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the US Pharmaceuticals industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is SNYN.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNYN.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.9x
Fair PE Ratio34.7x

Price-To-Earnings vs Fair Ratio: SNYN.F is good value based on its Price-To-Earnings Ratio (22.9x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNYN.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$108.37
US$120.72
+11.4%
6.1%US$129.57US$103.66n/a21
Jan ’26US$95.10
US$118.43
+24.5%
7.5%US$128.00US$88.46n/a21
Dec ’25US$95.81
US$120.73
+26.0%
7.4%US$133.33US$95.24n/a21
Nov ’25US$108.74
US$123.40
+13.5%
7.4%US$136.29US$97.35n/a21
Oct ’25US$114.50
US$126.73
+10.7%
8.9%US$145.28US$94.99n/a22
Sep ’25US$113.65
US$121.16
+6.6%
8.5%US$138.15US$93.94n/a22
Aug ’25US$100.25
US$119.01
+18.7%
8.4%US$135.35US$92.04n/a23
Jul ’25US$95.50
US$116.06
+21.5%
9.2%US$134.22US$85.90n/a22
Jun ’25US$94.63
US$116.61
+23.2%
9.0%US$135.14US$86.49n/a22
May ’25US$100.00
US$115.24
+15.2%
9.0%US$133.72US$85.58n/a22
Apr ’25US$97.65
US$115.22
+18.0%
9.1%US$134.26US$85.93n/a22
Mar ’25US$94.50
US$115.36
+22.1%
9.9%US$135.11US$86.47n/a22
Feb ’25US$96.59
US$115.71
+19.8%
10.3%US$135.87US$86.96US$108.3722
Jan ’25US$99.61
US$115.77
+16.2%
11.1%US$138.35US$88.54US$95.1020
Dec ’24US$94.00
US$114.33
+21.6%
11.1%US$135.59US$86.78US$95.8120
Nov ’24US$92.50
US$112.60
+21.7%
11.5%US$141.60US$84.54US$108.7420
Oct ’24US$105.47
US$121.21
+14.9%
10.0%US$145.75US$95.06US$114.5021
Sep ’24US$105.33
US$121.92
+15.7%
9.6%US$148.66US$96.95US$113.6522
Aug ’24US$106.00
US$125.14
+18.1%
8.5%US$155.43US$101.19US$100.2521
Jul ’24US$106.15
US$120.66
+13.7%
8.5%US$150.40US$98.21US$95.5021
Jun ’24US$101.42
US$118.51
+16.9%
8.5%US$147.85US$96.55US$94.6321
May ’24US$111.32
US$120.80
+8.5%
6.9%US$136.64US$99.17US$100.0021
Apr ’24US$109.00
US$118.00
+8.3%
7.6%US$135.24US$92.70US$97.6522
Mar ’24US$94.00
US$113.95
+21.2%
8.8%US$132.21US$90.63US$94.5023
Feb ’24US$98.55
US$116.88
+18.6%
9.2%US$138.84US$92.20US$96.5923
Analyst Price Target
Consensus Narrative from 21 Analysts
US$120.89
Fair Value
10.4% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:13
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sanofi is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research